Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2007-03-13
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S321000, C514S322000, C546S198000, C546S199000, C546S201000
Reexamination Certificate
active
10076131
ABSTRACT:
The invention is directed to compounds of the formulaand the pharmaceutically acceptable salts thereofwherein Ar1is indole, benzimidazole, or benzotriazole, optionally substituted with lower alkyl (1–4C), halo, or lower alkoxy (1–4C);X1is CO or an isostere thereof;Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl;n is 0 or 1;Z is CH or N;X2is CH, CH2or an isostere thereof; andAr2consists of one or two phenyl moieties directly coupled to X2and optionally substituted by halo, nitro, alkyl (1–6C), CN or CF3, or by RCO, COOR, CONR2, NR2, OR or SR, wherein R is H or alkyl (1–6C) or by phenyl, itself optionally substituted by the foregoing substituents;with the proviso that if Z is N, X1is CO, and Ar1is indole, Ar1must be coupled to X1through the 2-, 5-, 6- or 7-position.These compounds are useful in the treatment of conditions associated with inflammation. In addition, the above compounds and other compounds described herein are useful in treating conditions associated with cardiac failure.
REFERENCES:
patent: 4088765 (1978-05-01), Winn et al.
patent: 4243806 (1981-01-01), Raeymaekers et al.
patent: 4454130 (1984-06-01), Tominaga et al.
patent: 4600715 (1986-07-01), Huth et al.
patent: 4737501 (1988-04-01), Tominago et al.
patent: 4886809 (1989-12-01), Tamada et al.
patent: 4937246 (1990-06-01), Sugihara et al.
patent: 5462934 (1995-10-01), Goto et al.
patent: 5698553 (1997-12-01), Prucher et al.
patent: 5714498 (1998-02-01), Kulagowski et al.
patent: 5726177 (1998-03-01), Halazy et al.
patent: 5795907 (1998-08-01), Kalindjian et al.
patent: 5817871 (1998-10-01), Dingerdissen et al.
patent: 6130235 (2000-10-01), Mavunkel et al.
patent: 6340685 (2002-01-01), Mavunkel et al.
patent: 6410540 (2002-06-01), Goehring et al.
patent: 6448257 (2002-09-01), Mavunkel et al.
patent: 6589954 (2003-07-01), Mavunkel et al.
patent: 2002/0115671 (2002-08-01), Goehring et al.
patent: 2005/0124649 (2005-06-01), Daun et al.
patent: 0 318 235 (1989-05-01), None
patent: 0 431 945 (1991-06-01), None
patent: 0 709 384 (1996-05-01), None
patent: 0 831 090 (1998-03-01), None
patent: 2-184673 (1990-07-01), None
patent: 3-161470 (1991-07-01), None
patent: WO-96/40143 (1996-12-01), None
patent: WO-97/26252 (1997-07-01), None
patent: WO-98/06715 (1998-02-01), None
patent: WO-98/07425 (1998-02-01), None
patent: WO-98/28292 (1998-07-01), None
patent: WO-99/61426 (1999-12-01), None
patent: WO-00/12074 (2000-03-01), None
patent: WO-01/07435 (2001-02-01), None
Buechi “New aspects of structure-activity relations” CA 67:107052 (1967).
Dominguez et al. “Design and synthesis of . . . ” CA 131:67650 (1999).
Cook et al. “Preparation of 2-aminopyridine . . . ” CA 132:347492 (2000).
Chembridge Product list, CHEMCATS AN 2002:1367700 (2002).
Kakihana et al. “Soluble beta-amyloid precursor . . . ” CA 135:313624 (2001).
Dominguez “Design and synthesis of potent . . . ” CA 131:67650 (1999).
Daun et al. “Preparation of deazazpurines . . . ” CA 139:117268 (2003).
Wyngaarden “Cecil textbook of medicine” p. 1397-1398 (1983).
Lin et al. “Expression of interleukin . . . ” CA 138:220242 (2003).
Berczi et al. “Cytokine and . . . ” CA 140:75526 (2003).
Adeghate “An update on the biology . . . ”CA 142:17044 (2004).
Heiman et al. “Cytokin stimulated . . . ” CA 142:296578 (2005).
Wyngaarden “Cecil textbook of medicine” p. 1397-1399 (1983).
“Trilateral project B3b . . . Theme: comparative study on reach through claims” Nov. 2001, p. 1.
Cohen et al. “Cytokine function . . . ” CA 125:31527 (1996).
King F. D. “Medicinal Chemistry; principle and practice” p. 206-209 (1994).
Patani et al. “Bioisosterism: a rational approach in drug design” Chem. Rev. v. 96, p. 3147-3148 (1996).
Dominguez et al. :Design and synthesis . . . CA 131:67650 (1999).
Cook et al. Preparation of 2-aminopyridine . . . CA 132:347492 (2000).
Kakihana et al. “Solubel beta amyloid . . . ” CA 135:313624 (2001).
Heat failure, definition from Merck Mannuel.
Vasculitis, definition from Merck Mannuel.
Wang et al. “Cardiac muscle cell hypertrophy . . . ” J. Biol. chem. 273, p. 2161-2168 (1998).
Adams et al., CA (1998) 128:201066.
Cegla et al., CA (1996) 126:31297.
De Clerck et al., Throm. Res. (1981) 23:1-12.
Dinarello, Chest (2000) 118(2):503-508.
Dukic et al., Arch. Pharm. (1997) 330:25-28.
Eyers et al., Chem. and Biol. (1995) 5:321-328.
Fischer, CA (1996) 67:10051.
Foye's Principles of Medicinal Chemistry, 5th ed., (2002) pp. 56-57.
Gassman, J. Am. Chem. Soc. (1974) 96(17):5495-5508.
Goehring et al., CA (2000) 132:203174.
Harbeson et al., CA (1988) 109:162909.
Hashimoto et al., Clinical and Experimental Allergy (1999-2000) 30:48-55.
International Search Report dated Jul. 29, 1999.
Jiang et al., J. Biol. Chem. (1996) 271:17920-17926.
Kumar et al., Biochem. Biophys. Res. Comm. (1997) 235:533-538.
Li et al., Biochem. Biophys. Res. Comm. (1996) 228:334-340.
Maguire et al., CA (1979) 92:122605.
Mittendorf et al., CA (2000) 132:265195.
Murai et al., Heterocycles (1992) 34(5):1017-1029.
Nakai et al., CA (1994) 121:222012.
Nakai et al., CA (1994) 121:221997.
Nick et al., J. Clin. Invest. (1997) 99:975-986.
Oelschlaeger et al., CA (1988) 109:73387.
Ogawa et al., CA (1988) 110:57613.
Otsuka Pharm., CA (1983) 100:51465.
Otsuka Pharm., CA (1983) 100:34414.
Otsuka Pharm., CA (1984) 100:68187.
Schmit et al., CA (1994) 122:53913.
Societe Des Usine Chemiques, CA (1968) 77:34584.
Stein et al., J. Biol. Chem. (1997) 272:19509-19517.
Tamada et al., CA (1989) 111:53834.
Von Strandtmann, CA (1971) 80:82713.
Wang et al., J. Biol. Chem. (1997) 272:23668-23674.
Wang et al., J. Biol. Chem. (1998) 273:2161-2168.
Yin et al., Nature (1998) 396:77-80.
Amendment Under 37 C.F.R. § 1.111, U.S. Appl. No. 09/316,761, filed Oct. 2002.
Lewicki John A.
Liu David Y.
Mavunkel Babu J.
Perumattam John J.
Schreiner George F.
Chang Celia
Scios Inc.
LandOfFree
Compounds and methods to treat cardiac failure and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods to treat cardiac failure and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods to treat cardiac failure and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3741990